Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Investor Daily.
Press releases published on May 2, 2025

Snail Games 報告稱 2025 年 4 月主要特許經營的擴展、新獨立恐怖 IP 發布及策略性發布增長帶來強大動力
卡爾弗城,加州, May 02, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商和發行商 Snail, Inc. (Nasdaq: Snal) (「Snail Games」或「公司」),今天重點介紹了其產品組合在 2025 年 4 月份的主要進程,包括 ARK 系列的擴展、Bellwright 的內容進程,以及公司獨立發行商品牌 Wandering Wizard 旗下的多個 IP 發布。 ARK 系列憑藉全新內容得以更上一層樓 Snail Games …

Pat DiCapo Acquires Shares of Full Circle Lithium
TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Mr. Pat DiCapo announces that he acquired 1,314,400 common shares (the “Shares”) of Full Circle Lithium Corp. ("Full Circle"), through a joint actor PowerOne Capital Markets Limited (the “Acquiror”) in a private …

Polymethyl Methacrylate (PMMA) Market worth $6.1 billion by 2029, at 3.4%, says MarketsandMarkets™
Delray Beach, FL, May 01, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Polymethyl Methacrylate (PMMA) Market size is projected to grow from USD 5.1 billion in 2024 to USD 6.1 billion by 2029, at a CAGR of 3.4%, as per the recent study by …

First National Bank Alaska Declares Dividend for Second Quarter 2025
ANCHORAGE, Alaska, May 01, 2025 (GLOBE NEWSWIRE) -- At the Board of Directors Meeting held April 30, 2025, a cash dividend of $4.00 per share was declared, payable on June 15, 2025, and distributed on June 16, 2025, to shareholders of record as of June 1, …

Equinor sells the Peregrino field for USD 3.5 billion
Equinor Brasil Energia Ltda., a subsidiary of Equinor (OSE: EQNR, NYSE: EQNR), has entered into agreements(1) with Brazilian company Prio Tigris Ltda., a subsidiary of PRIO SA (PRIO3.SA) for a sale of its 60% operated interest in the Peregrino field in …

Equinor selger Peregrino-feltet for 3,5 milliarder USD
Equinor Brasil Energia Ltda., et datterselskap av Equinor ASA (OSE:EQNR, NYSE: EQNR), har inngått avtaler(1) om salg av sin egenopererte eierandel på 60 prosent i Peregrino-feltet i Brasil med det brasilianske selskapet Prio Tigris Ltda. (PRIO3.SA). PRIO, …

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming …